Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd A Durham

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Therapeutic Innovation & Regulatory Science|November 10, 2018
How Did These Data Get Here? Recommendations for the Analysis of Data From ClinicalTrials.govTodd A Durham
Journal of Clinical Hypertension (Greenwich, Conn.)|February 10, 2015
Must new drugs be superior to those already available? The role of noninferiority clinical trialsJ Rick Turner, Todd A Durham
Journal of Clinical Hypertension (Greenwich, Conn.)|April 16, 2014
Meta-methodology: conducting and reporting meta-analysesJ Rick Turner, Todd A Durham
Statistical Methods in Medical Research|June 23, 2005
Randomization-based nonparametric methods for the analysis of multicentre trialsLisa M LaVange, Todd A Durham, Gary G Koch
The American Journal of Cardiology|September 5, 2017
Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial FibrillationTodd A Durham, Kristen Hassmiller Lich, Anthony J Viera, et al.
American Journal of Respiratory and Critical Care Medicine|December 21, 2010
Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung functionFrank J Accurso, Richard B Moss, Robert W Wilmott, et al.
Translational Vision Science & Technology|May 18, 2021
Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness ConsortiumTodd A Durham, Jacque L Duncan, Allison R Ayala, et al.
Eye & Contact Lens|July 29, 2016
Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye DiseaseMichael H Goldstein, Joseph R Martel, Kenneth Sall, et al.
Investigative Ophthalmology & Visual Science|March 16, 2022
The RUSH2A Study: Dark-Adapted Visual Fields in Patients With Retinal Degeneration Associated With Biallelic Variants in the USH2A GeneDavid G Birch, Lassana Samarakoon, Michele Melia, et al.
Investigative Ophthalmology & Visual Science|August 12, 2025
Progression of Dark-Adapted Visual Fields Over 3 Years in the Rate of Progression in USH2A-Related Retinal Degeneration (RUSH2A) StudyDavid G Birch, Jacque L Duncan, Lassana Samarakoon, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Therapeutic Innovation & Regulatory Science|November 10, 2018
How Did These Data Get Here? Recommendations for the Analysis of Data From ClinicalTrials.govTodd A Durham
Journal of Clinical Hypertension (Greenwich, Conn.)|February 10, 2015
Must new drugs be superior to those already available? The role of noninferiority clinical trialsJ Rick Turner, Todd A Durham
Journal of Clinical Hypertension (Greenwich, Conn.)|April 16, 2014
Meta-methodology: conducting and reporting meta-analysesJ Rick Turner, Todd A Durham
Statistical Methods in Medical Research|June 23, 2005
Randomization-based nonparametric methods for the analysis of multicentre trialsLisa M LaVange, Todd A Durham, Gary G Koch
The American Journal of Cardiology|September 5, 2017
Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial FibrillationTodd A Durham, Kristen Hassmiller Lich, Anthony J Viera, et al.
American Journal of Respiratory and Critical Care Medicine|December 21, 2010
Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung functionFrank J Accurso, Richard B Moss, Robert W Wilmott, et al.
Translational Vision Science & Technology|May 18, 2021
Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness ConsortiumTodd A Durham, Jacque L Duncan, Allison R Ayala, et al.
Eye & Contact Lens|July 29, 2016
Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye DiseaseMichael H Goldstein, Joseph R Martel, Kenneth Sall, et al.
Investigative Ophthalmology & Visual Science|March 16, 2022
The RUSH2A Study: Dark-Adapted Visual Fields in Patients With Retinal Degeneration Associated With Biallelic Variants in the USH2A GeneDavid G Birch, Lassana Samarakoon, Michele Melia, et al.
Investigative Ophthalmology & Visual Science|August 12, 2025
Progression of Dark-Adapted Visual Fields Over 3 Years in the Rate of Progression in USH2A-Related Retinal Degeneration (RUSH2A) StudyDavid G Birch, Jacque L Duncan, Lassana Samarakoon, et al.
Pageof 3